AArkstore enterprise 1thDecember 2014
Pulmonary Embolism (PE) Ther apeutics Pipeline Assessment and Market Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/60323/pulmonary-embolism-petherapeutics-pipeline-assessment-and-market-forecasts Published: Feb 2012 | No. Of Pages: 88 Pages PDF: $ 3995 | Site Licence : $ 7990 | Enterprise Wide Licence : $ 11985
Forecasts to 2019
Summary The industry analysis specialist, has released its new report, “Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Pulmonary Embolism Therapeutics market. The report identifies the key trends shaping and driving the global Pulmonary Embolism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pulmonary Embolism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Website : http://www.aarkstore.com/
AArkstore enterprise Scope The report provides information on the key drivers and challenges of the Pulmonary Embolism Therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pulmonary Embolism Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Pulmonary Embolism Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pulmonary Embolism Therapeutics market. - Analysis of key recent licensing and partnership agreements in Pulmonary Embolism Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Pulmonary Embolism Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pulmonary Embolism Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Website : http://www.aarkstore.com/
AArkstore enterprise - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Pulmonary Embolism Therapeutics market landscape? – Identify, understand and capitalize.
Special Discount on Global Data Market Research Reports: Click here an avail Discount offer on Global Data market research reports: http://www.aarkstore.com/discount.php Discount Valid till 31st December 2014 For Research Reports Call us on: +91 9987295242 OR Mail us at contact@aarkstore.com
Tables Of Contents 2 Pulmonary Embolism (PE) - Introduction 2.1 Overview 2.2 Epidemiology 2.3 Etiology 2.3.1 Stagnant Blood Flow 2.3.2 Coagulation 2.3.3 Damage to the Vein Walls
Website : http://www.aarkstore.com/
AArkstore enterprise 2.3.4 Other Risk Factors 2.4 Clinical Presentation/Symptoms 2.5 Diagnosis 2.5.1 Electrocardiography 2.5.2 Chest Radiography 2.5.3 Arterial Blood Gas (ABG) Determination 2.5.4 Computed Tomographic Pulmonary Angiography 2.5.5 Ventilation-Perfusion Scanning 2.5.6 Magnetic Resonance Angiography 2.5.7 Biomarkers (Troponins and Brain Natriuretic Peptide) 2.5.8 Echocardiography (Transthoracic and Transesophageal) 2.6 Pathophysiology 2.7 Treatment 2.7.1 Anticoagulation 2.7.2 Unfractionated Heparin (UFH) 2.7.3 Low Molecular Weight Heparin (LMWH) 2.7.4 Indirect Factor Xa Inhibitors 2.7.5 Thrombolytic agents 2.7.6 Warfarin 2.8 Other Procedures and Devices for Pulmonary Embolism 2.8.1 Pulmonary Embolectomy 2.8.2 Vena Caval Interruption 2.9 GlobalData Pipeline Report Guidance
Website : http://www.aarkstore.com/
AArkstore enterprise 3 Pulmonary Embolism Therapeutics - Market Characterization 3.1 Overview 3.2 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Global 3.3 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Global 3.4 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The US 3.5 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The US 3.6 Pulmonary Embolism Therapeutics Market Size (2006-2011) - France 3.7 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - France 3.8 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Germany 3.9 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Germany 3.10 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Italy 3.11 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Italy 3.12 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Spain 3.13 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Spain 3.14 Pulmonary Embolism Therapeutics Market Size (2006-2011) - The UK 3.15 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - The UK 3.16 Pulmonary Embolism Therapeutics Market Size (2006-2011) - Japan 3.17 Pulmonary Embolism Therapeutics Market Forecast (2011-2019) - Japan 3.18 Drivers and Barriers for the Pulmonary Embolism Therapeutics Market 3.18.1 Drivers for the Pulmonary Embolism Therapeutics Market 3.18.2 Barriers for the Pulmonary Embolism Therapeutics Market 3.19 Opportunity and Unmet Need 3.20 Key Takeaway
Website : http://www.aarkstore.com/
AArkstore enterprise 4 Pulmonary Embolism Therapeutics Market - Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profiles of the Major Marketed Products in the Pulmonary Embolism Therapeutics Market - Heparin Class 4.3.1 Enoxaparin (Lovenox or Clexane) 4.3.2 Dalteparin (Fragmin) 4.3.3 Warfarin 4.3.4 Xarelto 4.3.5 Fondaparinux (Arixtra) 4.3.6 Apixaban (Eliquis) 4.4 Key Takeaway 5 Pulmonary Embolism Therapeutics Market - Pipeline Assessment 5.1 Overview 5.1.1 Pulmonary Embolism Therapeutics –Phase III Clinical Pipeline 5.1.2 Pulmonary Embolism Therapeutics – Phase II Clinical Pipeline 5.1.3 Pulmonary Embolism Therapeutics – Regulatory and Phase I Clinical Pipeline 5.1.4 Pulmonary Embolism Therapeutics – Preclinical and Discovery Clinical Pipeline 5.2 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Mechanism of Action 5.3 Pulmonary Embolism Therapeutics Market - Technology Trends Analytical Framework 5.4 Pulmonary Embolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 5.5 Pulmonary Embolism Therapeutics - Promising Drugs under Clinical Development 5.6 Molecule Profile for Promising Drugs under Clinical Development 5.6.1 Edoxaban
Website : http://www.aarkstore.com/
AArkstore enterprise 5.7 Key Takeaway 6 Pulmonary Embolism Therapeutics - Clinical Trials Mapping 6.1 Clinical Trials by Region/Country 6.2 Clinical Trials by Phase of Clinical Development 6.3 Clinical Trials by Trial Status 6.4 Prominent and Overall Sponsors 6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 7 Pulmonary Embolism Therapeutics - Strategic Assessment 7.1 Key Events Impacting the Future Market 7.2 Future Market Competition Scenario 8 Pulmonary Embolism Therapeutics - Future Players 8.1 Introduction 8.1.1 Boehringer Ingelheim GmbH 8.1.2 Bristol-Myers Squibb 8.1.3 Daiichi Sankyo 8.1.4 Pfizer Inc. 8.1.5 Sanofi 9 Pulmonary Embolism Therapeutics Market - Appendix 9.1 Market Definition 9.2 Abbreviations 9.3 Methodology 9.3.1 Coverage 9.3.2 Secondary Research
Website : http://www.aarkstore.com/
AArkstore enterprise 9.3.3 Forecasting 9.3.4 Primary Research 9.3.5 Expert Panel Validation 9.4 Contact Us 9.5 Disclaimer 9.6 Bibliography
List Of Tables Table 1: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006–2011 Table 2: Pulmonary Embolism Therapeutics Market, Global, Market Forecasts ($m), 2011–2019 Table 3: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006–2011 Table 4: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011–2019 Table 5: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006–2011 Table 6: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011–2019 Table 7: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006–2011 Table 8: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011–2019 Table 9: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006–2011 Table 10: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011–2019 Table 11: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006–2011 Table 12: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011–2019 Table 13: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006–2011 Table 14: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011–2019 Table 15: Pulmonary Embolism Market, Japan, Revenue ($m), 2006–2011
Website : http://www.aarkstore.com/
AArkstore enterprise Table 16: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011–2019 Table 17: Major Marketed Products Comparison in the Pulmonary Embolism Therapeutics Market, 2011 Table 18: Pulmonary Embolism Therapeutics Market – Phase III Clinical Pipeline, 2011 Table 19: Pulmonary Embolism Therapeutics Market – Phase II Clinical Pipeline, 2011 Table 20: Pulmonary Embolism Therapeutics Market – Phase I Clinical Pipeline, 2011 Table 21: Pulmonary Embolism Therapeutics Market – Preclinical Pipeline, 2011 Table 22: Pulmonary Embolism Therapeutics – Most Promising Drugs under Clinical Development, 2011 Table 23: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials, 2011 Table 24: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011 Table 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Status of Development, 2011 Table 26: Pulmonary Embolism Therapeutics Market, Global, Sponsors, 2011 Table 27: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011
List Of Figures Figure 1: Pulmonary Embolism Clinical Presentation Figure 2: Pulmonary Embolism Therapeutics Market, Global, Revenues ($m), 2006–2011 Figure 3: Pulmonary Embolism Therapeutics Market, Global, Market Forecast ($m), 2011–2019 Figure 4: Pulmonary Embolism Therapeutics Market, The US, Revenue ($m), 2006–2011 Figure 5: Pulmonary Embolism Therapeutics Market, The US, Market Forecasts ($m), 2011–2019 Figure 6: Pulmonary Embolism Therapeutics Market, France, Revenue ($m), 2006–2011 Figure 7: Pulmonary Embolism Therapeutics Market, France, Market Forecast ($m), 2011–2019 Figure 8: Pulmonary Embolism Therapeutics Market, Germany, Revenue ($m), 2006–2011
Website : http://www.aarkstore.com/
AArkstore enterprise Figure 9: Pulmonary Embolism Therapeutics Market, Germany, Market Forecast ($m), 2011–2019 Figure 10: Pulmonary Embolism Therapeutics Market, Italy, Revenue ($m), 2006–2011 Figure 11: Pulmonary Embolism Therapeutics Market, Italy, Market Forecast ($m), 2011–2019 Figure 12: Pulmonary Embolism Therapeutics Market, Spain, Revenue ($m), 2006–2011 Figure 13: Pulmonary Embolism Therapeutics Market, Spain, Market Forecast ($m), 2011–2019 Figure 14: Pulmonary Embolism Therapeutics Market, The UK, Revenue ($m), 2006–2011 Figure 15: Pulmonary Embolism Therapeutics Market, The UK, Market Forecast ($m), 2011–2019 Figure 16: Pulmonary Embolism Therapeutics Market, Japan, Revenue ($m), 2006–2011 Figure 17: Pulmonary Embolism Therapeutics Market, Japan, Market Forecast ($m), 2011–2019 Figure 18: Opportunity and Unmet Need in the PE Therapeutics Market Figure 19: Strategic Competitor Assessment of the Marketed Products for Pulmonary Embolism, 2011 Figure 20: Pulmonary Embolism Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 Figure 21: Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline, 2011 Figure 22:Technology Trends Analytic Framework of the Pulmonary Embolism Pipeline – Description, 2011 Figure 23: Pulmonary Embolism Pipeline by Phase of Clinical Development, 2011 Figure 24: Pulmonary Embolism Market, Global, Clinical Trials by Country, 2011 Figure 25: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Phase, 2011 Figure 26: Pulmonary Embolism Therapeutics Market, Global, Clinical Trials by Stage of Development, 2011 Figure 27: Pulmonary Embolism Therapeutics Market, Global, Prominent Sponsors, 2011 Figure 28: Pulmonary Embolism Therapeutics Market, Global, Overall Sponsors, 2011 Figure 29: Pulmonary Embolism Therapeutics Market, Global, Companies by Phase, 2011 Figure 30: Pulmonary Embolism Therapeutics Market, Drivers and Restraints, 2011 Figure 31: Implications for Future Market Competition in the Pulmonary Embolism Therapeutics Market, 2011
Website : http://www.aarkstore.com/
AArkstore enterprise Figure 32: Pulmonary Embolism Therapeutics Market – Clinical Pipeline by Company, 2011 Figure 33: GlobalData Market Forecasting Model
Discount reports: Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Xerostomia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
About Aarkstore Enterprise Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
You can order full Report with TOC and Sample page visit: http://www.aarkstore.com/pharmaceuticals-healthcare/60323/pulmonary-embolism-petherapeutics-pipeline-assessment-and-market-forecasts
Website : http://www.aarkstore.com/
AArkstore enterprise Contact Details: Aarkstore Enterprise Phone: +91 998 729 5242 Email: enquiry@aarkstore.com Our Website: http://www.aarkstore.com Facebook: https://www.facebook.com/aarkstoredotcom Linkedin: http://www.linkedin.com/company/aarkstore-enterprise
Website : http://www.aarkstore.com/